Products
Acute Myeloid Leukemia (AML)
Disease, Population & Market Potential Overview
AML is one of the most deadly and most common type of acute leukemia in adults. According to the American Cancer Society, the incidence of AML is about 12,000 patients per year in the U.S. with approximately 8,000 deaths per year. The disease is characterized by uncontrolled proliferation of immature blast cells in bone marrow and generally has a poor prognosis, particularly in frontline elderly and relapsed/refractory populations. Once diagnosed with AML, patients typically receive induction and consolidation chemotherapy, with the majority achieving complete remission. However, about 70-80% of patients who achieve a first complete remission will relapse, with the median time in remission before relapse being only 8 months with current treatments. Less than 15% of relapsed patients survive long-term.
AML is one of the most deadly and most common type of acute leukemia in adults. According to the American Cancer Society, the incidence of AML is about 12,000 patients per year in the U.S. with approximately 8,000 deaths per year. The disease is characterized by uncontrolled proliferation of immature blast cells in bone marrow and generally has a poor prognosis, particularly in frontline elderly and relapsed/refractory populations. Once diagnosed with AML, patients typically receive induction and consolidation chemotherapy, with the majority achieving complete remission. However, about 70-80% of patients who achieve a first complete remission will relapse, with the median time in remission before relapse being only 8 months with current treatments. Less than 15% of relapsed patients survive long-term.